Biofarm (FRA:H3D) Cyclically Adjusted Revenue per Share: €0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H3D Biofarm SA FRA:H3D
70 GF Score
Price €0.24
GF Value €0.15
! 5 Warning Signs
View Full Analysis

What is Biofarm Cyclically Adjusted Revenue per Share?

Biofarm FRA:H3D -1.26% 70 Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus rates FRA:H3D with a GF Score™ of 70/100 and a GF Value™ of €0.15. The stock has 5 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biofarm's adjusted revenue per share for the three months ended in Mar. 2026 was €0.018. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biofarm's average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biofarm was 1.40% per year. The lowest was 0.00% per year. And the median was 0.70% per year.

As of today (2026-07-29), Biofarm's current stock price is €0.235. Biofarm's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.00. Biofarm's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biofarm was 5.34. The lowest was 2.18. And the median was 2.81.


Biofarm  (FRA:H3D) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biofarm was 5.34. The lowest was 2.18. And the median was 2.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biofarm Cyclically Adjusted Revenue per Share Related Terms


Biofarm Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biofarm's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofarm Cyclically Adjusted Revenue per Share Chart

Biofarm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biofarm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:H3D vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofarm Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofarm's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biofarm's Cyclically Adjusted PS Ratio falls into.


FRA:H3D
70GF Score
Biofarm SA FRA:H3D
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofarm Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biofarm's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.018/330.2130*330.2130
=0.018

Current CPI (Mar. 2026) = 330.2130.

Biofarm Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.007 241.018 0.010
201609 0.007 241.428 0.010
201612 0.009 241.432 0.012
201703 0.007 243.801 0.009
201706 0.009 244.955 0.012
201709 0.008 246.819 0.011
201712 0.009 246.524 0.012
201803 0.008 249.554 0.011
201806 0.008 251.989 0.010
201809 0.009 252.439 0.012
201812 0.010 251.233 0.013
201903 0.009 254.202 0.012
201906 0.009 256.143 0.012
201909 0.008 256.759 0.010
201912 0.012 256.974 0.015
202003 0.012 258.115 0.015
202006 0.008 257.797 0.010
202009 0.010 260.280 0.013
202012 0.012 260.474 0.015
202103 0.012 264.877 0.015
202106 0.011 271.696 0.013
202109 0.012 274.310 0.014
202112 0.012 278.802 0.014
202203 0.015 287.504 0.017
202206 0.012 296.311 0.013
202209 0.014 296.808 0.016
202212 0.013 296.797 0.014
202303 0.018 301.836 0.020
202306 0.013 305.109 0.014
202309 0.013 307.789 0.014
202312 0.010 306.746 0.011
202403 0.014 312.332 0.015
202406 0.013 314.175 0.014
202409 0.017 315.301 0.018
202412 0.011 315.605 0.012
202503 0.018 319.799 0.019
202506 0.013 322.561 0.013
202509 0.019 324.800 0.019
202512 0.011 324.054 0.011
202603 0.018 330.213 0.018

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Biofarm (FRA:H3D) has a Cyclically Adjusted Revenue per Share of €0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biofarm and its competitors.
Is Biofarm's Cyclically Adjusted Revenue per Share too high?
Biofarm's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Biofarm has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Biofarm's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biofarm and its competitors. Biofarm's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Biofarm (FRA:H3D) has a current Cyclically Adjusted Revenue per Share of €0.00. The stock's GF Value™ is €0.15, compared to a current price of €0.24 — trading 56.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Biofarm's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biofarm (FRA:H3D), the current Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofarm (FRA:H3D) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of €0.24 is trading 56.7% above its estimated GF Value™ of €0.15.

Key valuation signals for FRA:H3D:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €0.15 vs. price of €0.24 (56.7% above fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the FRA:H3D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofarm Business Description

Other Exchanges BIO:Romania
Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
70GF Score

Get the complete analysis for FRA:H3D

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.15
GF Value